Navigation Links
Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
Date:3/26/2008

tatements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabilities, our dependence on third-party manufacturers and value added resellers, our ability to hire and retain skilled personnel, our volatile stock price, and other risks detailed in Repligen's filings with th
'/>"/>
SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
2. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
7. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
8. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. Prolexys Pharmaceuticals Initiates Phase 1 Study
11. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- 4WEB Medical announces the formal launch of the ... on the market today at this weekend,s American ... Chicago .  The Osteotomy Truss System is a ... 74 size options included in one versatile set. Previously ... to 18 implant sizes, which limited a surgeon,s ability ...
(Date:9/19/2014)... Conn. , Sept. 19, 2014 UBM ... , a leading online community to help oncologists and ... information available regarding the use of targeted therapies and ... cancer research and treatment.  Every September, ... a way to raise awareness about blood cancers—helping to ...
(Date:9/19/2014)... , Sept. 19, 2014  Pressure BioSciences, ... announced it has received and approved all parts ... instruments and has begun to manufacture the new ... instrument will be ready for shipment by mid-October ... and released at a rate of about one ...
Breaking Medicine Technology:4WEB Medical Unveils 3D-Printed Osteotomy Truss System 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3
... 2011 ,   EP ... of the Year Award at the European Mediscience,Awards, sponsored ... award, which honours clear and concise commentary in the,pharma ... research houses or specialist websites dedicated to,providing sharp, perceptive ...
... 24, 2011 New Phase 2 clinical trial data ... of Medicine show that patients with moderate to ... bardoxolone methyl for 52 weeks experienced a sustained improvement ... by estimated glomerular filtration rate (eGFR). The data were ...
Cached Medicine Technology:EP Vantage Wins Commentator of the Year Award at European Mediscience Awards 2011 2EP Vantage Wins Commentator of the Year Award at European Mediscience Awards 2011 3New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes 2New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes 3New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes 4
(Date:9/20/2014)... Weight Destroyer , a weight loss ... Wren that has already helped tens of thousands of ... like high blood pressure, high cholesterol, and accelerated aging ... investigative review. , “Weight Destroyer is totally turning ... showing people what is truly effective when it comes ...
(Date:9/20/2014)... 2014 Increases in household, construction ... waste treatment volumes. However, government regulations and higher ... landfill. According to IBISWorld industry analyst Alen Allday, ... aimed at reducing the volume of waste generated, ... recovered.” Still, a large proportion of waste generated ...
(Date:9/20/2014)... 2014 The print component of ... of the Calgary Herald, with a circulation of ... 270,000. The digital component is distributed nationally through ... network of top news sites and partner outlets. ... visit http://www.worklifebalanceinfo.ca . , The publication features ...
(Date:9/20/2014)... Ticket Down is a reputable ... her 2015 “Honeymoon Tour.” This well-known ticket exchange is ... , In early 2015, fans will have a chance to ... North America. Twenty-one-year-old Ariana Grande will hit the road in ... to 25 cities across the United States and Canada. Grande, ...
(Date:9/20/2014)... The excitement is building up once again for the annual Mayberry ... the Surry Arts Council will be celebrating its 25th year hosting ... still fans of the Andy Griffith Show. , ... from 1960 through 1968. The show ranked by TV Guide ... Airy, North Carolina is where the show was filmed calling it ...
Breaking Medicine News(10 mins):Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 2Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 3Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Getting ‘Wellthy’: Mediaplanet’s “Work-Life Wellness” campaign puts stock in the personal and economic gains of healthy, vital workplace environments for Canadians 2Health News:Ariana Grande Tickets in New York, Philadelphia, Orlando, Fairfax, Worcester, Toronto, Uncasville, Detroit, Miami, Pittsburgh, Cleveland, and Atlanta On Sale Today 2Health News:Ariana Grande Tickets in New York, Philadelphia, Orlando, Fairfax, Worcester, Toronto, Uncasville, Detroit, Miami, Pittsburgh, Cleveland, and Atlanta On Sale Today 3Health News:Mayberry Days Parade Cars will be Provided by Mount Airy Toyota and Mount Airy Chrysler Dodge Jeep Ram 2
... with the non-profit organization HopeLab to deliver innovative interventions ... young people with chronic illnesses . Their first joint ... and young adults with cancer by offering free of ... works. It gives young people with cancer a sense ...
... are more active and have less body fat than ... today at the 54th American College of Sports Medicine ... associated with higher levels of self-reported leisure-time physical activity ... weight, status, and neighborhood, environment, walkability, and income between ...
... lawmakers to set aside 30 billion dollars over five years ... proposal fell short of funds needed to battle the global ... would visit Africa in June to assess HIV/AIDS-fighting strategies in ... works and what does not in battling the deadly disease. ...
... holy city of Najaf on Friday after receiving treatment for ... of the most powerful parties in the parliament, spent nearly ... in the United States and treatment in Iran. ... there for a long time, after he finished his initial ...
... study has found that people can be encouraged to walk ... if they are given the right kind of help. ... the Scottish Physical Activity Research Collaboration (SPARColl), the study suggests ... of waysface to face advice or telephone support, using pedometers, ...
... found three new drugs that may help transform the ... thus giving hope for chronically infected patients. ,The ... Hiroyu Hatano, and Steven Deeks at San Francisco General ... new drugs are the HIV integrase inhibitors, R5 inhibitors, ...
Cached Medicine News:Health News:CIGNA HealthCare Teams With HopeLab to Help Blast Teen Cancer 2Health News:Dog Owners More Active, Leaner 2Health News:Bush Seeks Doubling of AIDS-fighting Funds 2Health News:Top Iraqi Shiite Leader Returns Home 2
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Stat Detection of Soluble Fibrin Monomer Complexes by the Hemagglutination Technique, 32 tests....
Batch Detection of Soluble Fibrin Monomer Complexes by the Hemagglutination Technique, 40 tests....
For use with catalog #0454....
Medicine Products: